PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1628131
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1628131
Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
The Global Cancer Diagnostics Market, valued at USD 158.7 billion in 2024, is poised for steady growth at a CAGR of 9% between 2025 and 2034. Cancer diagnostics encompasses a range of tests and technologies designed to detect and identify cancer at its earliest stages. The primary aim is to determine the type, location, and progression of cancer to enable timely and effective treatment, thereby improving patient outcomes.
The market expansion is primarily driven by the increasing global prevalence of cancer. Projections indicate a sharp rise in the number of cancer cases, emphasizing the critical need for advanced diagnostic methods. This growing burden is boosting the adoption of technologies such as imaging and molecular diagnostics, which play a crucial role in early detection and accurate diagnosis.
Technological advancements in healthcare systems, particularly in developing regions, are further propelling market growth. Investments in healthcare infrastructure and the introduction of cutting-edge tools, including telemedicine, have made cancer diagnostics more accessible and efficient. These innovations support faster and more precise detection, improving overall patient care.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $158.7 Billion |
| Forecast Value | $372.5 Billion |
| CAGR | 9% |
The market is segmented by application into tumor biomarker tests, imaging, biopsy, liquid biopsy, immunohistochemistry, and in situ hybridization. Imaging accounts for the largest revenue share, capturing 63.6% in 2024. Increasing awareness about breast cancer screenings and developing advanced imaging technologies are key contributors to this segment's dominance.
By cancer type, the market is categorized into several segments, including bladder, breast, colorectal, endometrial, kidney, liver, lung, and prostate cancer. Liver and lung cancers together accounted for 18.4% of the market share in 2024 and are expected to see robust growth through 2034. Factors such as environmental triggers and unhealthy lifestyle habits are driving the increased incidence of these cancers, highlighting the urgent need for effective diagnostic solutions.
End-user segments include hospitals, diagnostic laboratories, imaging centers, and cancer research institutes. Hospitals dominate this category due to their widespread adoption of advanced diagnostic equipment and the presence of skilled healthcare professionals. Favorable reimbursement policies further support segment growth, ensuring access to high-quality diagnostic services.
Regionally, the U.S. is expected to experience significant market expansion, with projections estimating the market size to reach USD 135 billion by 2034. Factors like an aging population and increased demand for advanced diagnostic tools contribute to the growth in this region.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of cancer globally
- 3.2.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness
- 3.2.1.3 Growing number of diagnostic laboratories in developing countries
- 3.2.1.4 Technology advancements in developed countries
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High capital investment coupled with high costs associated with diagnostic imaging systems
- 3.2.2.2 Risk related with high radiation exposure affecting use of CT scanner
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
- 3.6 Future market trends
- 3.7 Gap analysis
- 3.8 Porter's analysis
- 3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Tumor biomarkers tests
- 5.3 Imaging
- 5.3.1 Ultrasound and radiology
- 5.3.2 Mammography
- 5.3.3 MRI scan
- 5.3.4 PET scan
- 5.3.5 CT scan
- 5.3.6 SPECT and other imaging
- 5.4 Biopsy
- 5.5 Liquid biopsy
- 5.6 Immunohistochemistry
- 5.7 In situ hybridization
Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Bladder cancer
- 6.3 Breast cancer
- 6.4 Colon and rectal cancer
- 6.5 Endometrial cancer
- 6.6 Kidney cancer
- 6.7 Leukemia
- 6.8 Liver and lung cancer
- 6.9 Melanoma
- 6.10 Non-hodgkin lymphoma
- 6.11 Pancreatic cancer
- 6.12 Prostate cancer
- 6.13 Thyroid cancer
- 6.14 Other cancer types
Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Diagnostic laboratories
- 7.4 Diagnostic imaging centers
- 7.5 Cancer research institutes
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Russia
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
Chapter 9 Company Profiles
- 9.1 Abbott Laboratories
- 9.2 AB Sciex Pte
- 9.3 Agilent Technologies
- 9.4 Becton, Dickinson and Company
- 9.5 Biocare Medical
- 9.6 Biocartis
- 9.7 Biomerieux
- 9.8 Bio-Rad Laboratories
- 9.9 Danaher Corporation
- 9.10 F-Hoffmann-La Roche
- 9.11 GE Healthcare
- 9.12 Hologic
- 9.13 Johnson & Johnson
- 9.14 Koninklijke Philips
- 9.15 Myriad Genetics
- 9.16 QIAGEN
- 9.17 Siemens Healthineers
- 9.18 Sysmex Corporation
- 9.19 Thermo Fisher Scientific
